Pharsight

Vemlidy generic

Vemlidy is an antiviral medication owned by Gilead Sciences Inc. The active ingredient in Vemlidy is tenofovir alafenamide fumarate. The drug was first authorized for market use on 10 November, 2016.

When will Vemlidy generic be available?

The generic version of Vemlidy could potentially become available after 15 February, 2033. This release date is speculated based on the expiration date of its last patent, US9296769*PED. The expired patent, US7803788, is not a hindrance to the release of Vemlidy generics.

Vemlidy uses

Vemlidy is primarily used for the treatment of chronic hepatitis B in adult patients. The effectiveness of this drug comes from its active ingredient, tenofovir alafenamide fumarate, which is an antiviral medication.

Vemlidy patent expiration

Vemlidy is protected by 7 patents, with the latest one (US9296769*PED entitled 'Tenofovir alafenamide hemifumarate') expiring on 15 February, 2033. One of the patents (US7803788) has already expired. For more insights into when a Vemlidy generic could become available, refer to the patent details provided. Below are the details of the patents:

EPO Oppostions filed on Vemlidy

Vemlidy dosage

Want to ask something?